Department of Internal Medicine, Diakonessenhuis Utrecht, the Netherlands.
Department of Geriatric Medicine, Diakonessenhuis Utrecht, the Netherlands.
Gynecol Oncol. 2019 May;153(2):391-398. doi: 10.1016/j.ygyno.2019.02.001. Epub 2019 Feb 14.
To assess long-term differences in health-related quality of life (HRQoL) of older ovarian cancer survivors compared to both an age-matched normative population and to younger survivors. In addition, the differential effect of chemotherapy on HRQoL between older and younger survivors was compared.
Ovarian cancer survivors (n = 348) diagnosed between 2000 and 2010, as registered by the Dutch population-based Eindhoven Cancer Registry, were invited to complete the EORTC QLQ-C30 HRQoL questionnaire in 2012. HRQoL outcomes of survivors were compared with an age-matched normative population and older survivors (≥70 years) were compared with younger survivors.
The questionnaire was returned by 191 ovarian cancer survivors (55%), 31% were aged ≥70 years (n = 59). Compared to the normative population, survivors ≥70 years scored lower on global health status and all functioning subscales except emotional functioning, and they reported more symptoms. Survivors aged <70 years only reported worse physical and cognitive functioning in comparison with the normative population. Most differences were of medium to small clinical relevance. Age appeared to moderate the effect of chemotherapy on HRQoL. Older survivors who had received chemotherapy experienced better physical functioning and less pain and insomnia while the opposite was found in younger survivors.
In comparison with an age-matched normative population, older ovarian cancer survivors report lower HRQoL scores than younger survivors. As this represents a selection of long-term survivors, future research should focus on the trajectory of HRQoL from diagnosis throughout treatment and follow-up to identify which factors are related to worse HRQoL in the entire older ovarian cancer population and whether timely interventions are able to improve HRQoL.
评估老年卵巢癌幸存者与年龄匹配的常模人群和年轻幸存者相比,长期健康相关生活质量(HRQoL)的差异。此外,还比较了化疗对老年和年轻幸存者 HRQoL 的不同影响。
荷兰基于人群的埃因霍温癌症登记处(Eindhoven Cancer Registry)登记的 2000 年至 2010 年间诊断为卵巢癌的幸存者(n=348)被邀请在 2012 年完成 EORTC QLQ-C30 HRQoL 问卷。将幸存者的 HRQoL 结果与年龄匹配的常模人群进行比较,并将≥70 岁的幸存者(n=59)与年轻幸存者进行比较。
共有 191 名卵巢癌幸存者(55%)返回了问卷,其中 31%年龄≥70 岁(n=59)。与常模人群相比,≥70 岁的幸存者在总体健康状况和所有功能子量表(除情感功能外)方面的得分较低,并且报告的症状较多。年龄<70 岁的幸存者仅报告与常模人群相比,身体和认知功能较差。大多数差异具有中等至较小的临床相关性。年龄似乎调节了化疗对 HRQoL 的影响。接受过化疗的老年幸存者在身体功能方面表现更好,疼痛和失眠较少,而年轻幸存者则相反。
与年龄匹配的常模人群相比,老年卵巢癌幸存者的 HRQoL 评分较低。由于这是长期幸存者的选择,未来的研究应集中在从诊断到治疗和随访的整个 HRQoL 轨迹上,以确定哪些因素与整个老年卵巢癌人群的 HRQoL 较差有关,以及及时的干预是否能够改善 HRQoL。